|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine antagonist
|
|
gptkbp:ATCCode
|
V03AB25
|
|
gptkbp:CASNumber
|
78755-81-4
|
|
gptkbp:chemicalFormula
|
C15H14FN3O3
|
|
gptkbp:color
|
white to off-white powder
|
|
gptkbp:contraindication
|
patients with benzodiazepine dependence
patients with epilepsy
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
40–80 minutes
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1981
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Flumazenil
|
|
gptkbp:IUPACName
|
ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
|
|
gptkbp:KEGGID
|
gptkb:D00544
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
competitive antagonist at the benzodiazepine site of the GABA-A receptor
|
|
gptkbp:MeSH_ID
|
D015242
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
303.29 g/mol
|
|
gptkbp:notEffectiveAgainst
|
opioid overdose
barbiturate overdose
alcohol intoxication
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancy_risk
|
potential risk to fetus
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
50%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1092
gptkb:DB01213
3257
3373
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
dizziness
seizures
agitation
|
|
gptkbp:solubility
|
sparingly soluble in water
|
|
gptkbp:synonym
|
gptkb:Anexate
gptkb:Lanexat
gptkb:Mazicon
gptkb:Romazicon
|
|
gptkbp:UNII
|
40P7XK9392
|
|
gptkbp:usedFor
|
reversal of benzodiazepine sedation
treatment of benzodiazepine overdose
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:year_of_approval
|
1987
|
|
gptkbp:bfsParent
|
gptkb:Antidotes
gptkb:Antidote
|
|
gptkbp:bfsLayer
|
5
|